MAIA Biotechnology, Inc., a clinical-stage biopharmaceutical firm specializing in targeted cancer immunotherapies, recently announced the participation of two independent directors in its private placement offering. Directors Stan V. Smith, Ph.D., and Ramiro Guerrero, JD, LL.M., invested in the offering, which raised a total of $1.08 million from all investors. Dr. Smith acquired 66,666 shares and an equivalent number of warrants for approximately $100,000, while Mr. Guerrero purchased 20,000 shares and warrants for $30,000. MAIA's Chairman and CEO, Vlad Vitoc, M.D., expressed confidence in the company's strategic direction, supported by the directors' consistent investments. Dr. Smith and Mr. Guerrero emphasized their belief in the potential of MAIA's telomere targeting science as a future standard of care for high-mortality cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.